Brief: Bioage Labs Inc - Announces Positive Interim Phase 1 Data For BGE-102
04/12/2025 14:09
Dec 4 (Reuters) - BIOAGE Labs Inc BIOA.O: BIOAGE LABS INC - ANNOUNCES POSITIVE INTERIM PHASE 1 DATA FOR BGE-102, A NOVEL BRAIN-PENETRANT NLRP3 INHIBITOR BIOAGE LABS INC - BGE-102 WELL-TOLERATED IN SAD AND INITIAL MAD COHORTS, WITH A PHARMACOKINETIC PROFILE SUPPORTING ONCE-DAILY ORAL DOSING Source text: ID:nGNX4blr0y Further company coverage: BIOA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioAge Labs
See all newsBrief: Bioage Labs Announces First Participant Dosed In Quell-Dme, A Phase 2 Trial Of Bge-102, A Novel Oral Nlrp3 Inhibitor, In Diabetic Macular Edema
BioAge Labs, Inc. reports results for the quarter ended June 30 - Earnings Summary
BioAge Labs Q1 collaboration revenue beats estimates on Novartis collaboration
BioAge Labs full-year collaboration revenue beats estimates
U.S. RESEARCH ROUNDUP-Chevron, GoDaddy, HP